Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Apretude | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
Apprilon | Doxycycline monohydrate | Rosacea | Do not list | Complete | ||
Apidra | Insulin glulisine | Diabetes, Mellitus (Type 1 & 2) | List in a similar manner to other drugs in class | Complete | ||
Anoro Ellipta | Umeclidinium/vilanterol | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
Amvuttra | vutrisiran | Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) | Reimburse with clinical criteria and/or conditions | Complete | ||
Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
Alvesco | Ciclesonide | asthma | List | Complete | ||
Alunbrig | Brigatinib | NSCLC | Do not reimburse | Complete | ||
Alunbrig | Brigatinib | (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete |